Journal article · 2025 · Open access

POS0998 CC312, A CD19-TARGETING, CO-STIMULATORY CD28 RECEPTOR-ACTIVATING TRI-SPECIFIC T CELL ENGAGER, FOR THE TREATMENT OF AUTOIMMUNE DISEASES

Ying Huang, Xian Zhang, Chunling Zhao, R Zhang, J. Zhen, F. Pan, Bo Jian Zheng, R. Dai

Annals of the Rheumatic Diseases, 84, 1111–1112 · Published 1 June 2025 · DOI 10.1016/j.ard.2025.06.353

Open full textCite this paper

In brief

“POS0998 CC312, A CD19-TARGETING, CO-STIMULATORY CD28 RECEPTOR-ACTIVATING TRI-SPECIFIC T CELL ENGAGER, FOR THE TREATMENT OF AUTOIMMUNE DISEASES” is a 2025 journal article by Ying Huang and 7 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 3 citations as of 20 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Annals of the Rheumatic Diseases.

Citations
3
Most cited in
2025 (2)
Authors
8

Abstract

Background: B cell depletion therapy (BCDT), such as monoclonal antibodies, bispecific T cell engagers and CAR-T, has an extensive history of effectively treating B cell malignancies. Certain BCDT monoclonal antibodies, e.g. rituximab, are also approved to treat several autoimmune diseases [1], however demonstrate poor B cells depletion in deep tissue which may limit the long-term disease control or remission in patients. Recently, anti-CD19 CAR-T therapies, through thorough depletion of pathogenic B cells and "resetting" of normal B cell populations, have achieved compelling preliminary clinical efficacy including multi-year drug-free remission in multiple autoimmune diseases [2, 3], however CAR-T modality continues to pose challenges regarding safety, cost, and logistical complexity. T Cell Engagers (TCEs) represent an attractive alternate option to CAR-T, with approved CD19-targeting bispecific TCE Blincyto demonstrating strong potential in RA [4]. However, existing bispecifics have displayed key limitations such as T cell exhaustion, poor T cell proliferation, and insufficient durability of response. Here, we developed the tri-specific TCE CC312, targeting CD3 and the key co-stimulatory receptor CD28 on T cells and CD19 on B cells. By adding critical CD28 "two signal" co-stimulation, CC312 showed efficacy consistent with CAR-T therapies, achieving greater CD4/CD8 T cell activation, proliferation, T cell survival and B cell depletion versus Blincyto in a prior study in B cell malignancies, indicating strong potential to treat autoimmune disease. Objectives: In the current study, the potential of CC312 in treating autoimmune disease was explored in translational models, including ex vivo studies with SLE/RA donor PBMCs, an in vivo efficacy study in SLE patient derived-PBMC NCG mouse models, etc. Methods: B cell killing of CC312 was assessed in ex vivo cytotoxicity assays using human peripheral blood mononuclear cells (PBMCs) isolated from patients with autoimmune disease. T cell activation, proliferation and memory cell differentiation were also evaluated in response to patient-derived PBMCs. Moreover, to evaluate CC312's durability of response compared with Blincyto, SLE/RA patient derived-T cells were repeat rechallenged with B cells from the same donor. The in vivo efficacy for SLE was investigated in an animal model in which NCG mice were engrafted with SLE patient-derived PBMCs. B cell depletion in blood was analyzed by flow cytometry and in kidney tissues by immunohistochemistry. Results: Ex vivo , CC312 induced a dose-dependent potent depletion of B cells in PBMCs derived from donors with autoimmune diseases, with EC 50 in pM range across donors and disease types. Compared with Blincyto, CC312 significantly enhanced T cell activation and proliferation due to CD28 co-stimulation. In addition, CC312 also exhibited augmented memory T cell differentiation…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Huang, Y., Zhang, X., Zhao, C., Zhang, R., Zhen, J., Pan, F., Zheng, B. J., & Dai, R. (2025). POS0998 CC312, A CD19-TARGETING, CO-STIMULATORY CD28 RECEPTOR-ACTIVATING TRI-SPECIFIC T CELL ENGAGER, FOR THE TREATMENT OF AUTOIMMUNE DISEASES. Annals of the Rheumatic Diseases, 84, 1111–1112. https://doi.org/10.1016/j.ard.2025.06.353

MLA 9

Huang, Ying, et al. “POS0998 CC312, A CD19-TARGETING, CO-STIMULATORY CD28 RECEPTOR-ACTIVATING TRI-SPECIFIC T CELL ENGAGER, FOR THE TREATMENT OF AUTOIMMUNE DISEASES.” Annals of the Rheumatic Diseases, vol. 84, 2025, pp. 1111–1112. https://doi.org/10.1016/j.ard.2025.06.353.

Chicago

Huang, Ying, Xian Zhang, Chunling Zhao, R Zhang, J. Zhen, F. Pan, Bo Jian Zheng, and R. Dai. 2025. “POS0998 CC312, A CD19-TARGETING, CO-STIMULATORY CD28 RECEPTOR-ACTIVATING TRI-SPECIFIC T CELL ENGAGER, FOR THE TREATMENT OF AUTOIMMUNE DISEASES.” Annals of the Rheumatic Diseases 84: 1111–1112. https://doi.org/10.1016/j.ard.2025.06.353.

Harvard

Huang, Y. et al. (2025) ‘POS0998 CC312, A CD19-TARGETING, CO-STIMULATORY CD28 RECEPTOR-ACTIVATING TRI-SPECIFIC T CELL ENGAGER, FOR THE TREATMENT OF AUTOIMMUNE DISEASES’, Annals of the Rheumatic Diseases, 84, pp. 1111–1112. doi:10.1016/j.ard.2025.06.353.

IEEE

Y. Huang et al., “POS0998 CC312, A CD19-TARGETING, CO-STIMULATORY CD28 RECEPTOR-ACTIVATING TRI-SPECIFIC T CELL ENGAGER, FOR THE TREATMENT OF AUTOIMMUNE DISEASES,” Annals of the Rheumatic Diseases, vol. 84, pp. 1111–1112, 2025, doi: 10.1016/j.ard.2025.06.353.

BibTeX

@article{huang2025targeting,
  title     = {{POS0998 CC312, A CD19-TARGETING, CO-STIMULATORY CD28 RECEPTOR-ACTIVATING TRI-SPECIFIC T CELL ENGAGER, FOR THE TREATMENT OF AUTOIMMUNE DISEASES}},
  author    = {Huang, Ying and Zhang, Xian and Zhao, Chunling and Zhang, R and Zhen, J. and Pan, F. and Zheng, Bo Jian and Dai, R.},
  journal   = {Annals of the Rheumatic Diseases},
  year      = {2025},
  volume    = {84},
  pages     = {1111--1112},
  doi       = {10.1016/j.ard.2025.06.353},
  url       = {https://doi.org/10.1016/j.ard.2025.06.353}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology

  • CD19
  • CD28 costimulation
  • CD3
  • autoimmune disease
  • systemic lupus erythematosus
  • rheumatoid arthritis
  • B-cell depletion
  • T cell activation

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Huang, Y., Zhang, X., Zhao, C., Zhang, R., Zhen, J., Pan, F., Zheng, B. J., & Dai, R. (2025). POS0998 CC312, A CD19-TARGETING, CO-STIMULATORY CD28 RECEPTOR-ACTIVATING TRI-SPECIFIC T CELL ENGAGER, FOR THE TREATMENT OF AUTOIMMUNE DISEASES. Annals of the Rheumatic Diseases, 84, 1111–1112. https://doi.org/10.1016/j.ard.2025.06.353

How many times has this paper been cited?

3 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the full text from this page.

Who wrote this paper?

Ying Huang, Xian Zhang, Chunling Zhao, R Zhang, J. Zhen, F. Pan, Bo Jian Zheng, R. Dai.

What is the DOI of this paper?

10.1016/j.ard.2025.06.353, permanently at https://doi.org/10.1016/j.ard.2025.06.353. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.